Buscar
Congreso SOLACI
HomeAHA 2013.Day 2

Day 2

Ver Categoría
Day 2

VISTA 16: anti-inflammatory agent in acute coronary syndromes

There is evidence that inflammation would have an impact on the prognosis of patients experiencing acute coronary...
solaci -
Ver más
Day 2

TOPCAT: Spironolactone in heart failure with preserved ejection fraction

The aldosterone blockade has shown benefit in the treatment of heart failure with systolic dysfunction after stroke....
solaci -
Ver más
Day 2

Plastic versus mitral valve replacement in ischemic mitral regurgitation

Unlike degenerative mitral insufficiency, ischemic failure is due to an increase in the left ventricular cavity, the...
solaci -
Ver más
Day 2

MINERVA trial: DDDR versus DDDRP-MVP in patients with bradycardia

The sinus node disease is approximately 50 % of pacemaker implants. Atrial fibrillation is a frequent comorbidity...
solaci -
Ver más
Day 2

HF ROSE: Dopamine and Neseritide in heart failure associated with renal dysfunction

Previous small studies have suggested that low-dose dopamine or neseritide can enhance congestive signs of acute heart...
solaci -
Ver más
Day 2

MICROCLINIC: A healthy lifestyle can influence others

This randomized study conducted in a rural area consisted of an educational program of 9-10 months to...
solaci -
Ver más
Day 2

Promoting cardiovascular health in the preschool age

Cardiovascular disease is the worldwide leading cause of death. Changes in lifestyle, diet and sedentary routine have...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Evolution of Small Balloon-Expandable Valves

Dr. Carlos Fava - 0
Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

solaci - 0
Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

Dr. Carlos Fava - 0
The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

Noticias Institucionales

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Arequipa Sessions 2024: Meet the International Guests

solaci - 0
The Arequipa Sessions 2024 is getting closer and closer. Meet the international guests who will share their knowledge for 2 days at a high-level...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad